Sobetirome vs Tesofensine
Tesofensine has Phase II weight-loss efficacy data; sobetirome has only early Phase I target-engagement/lipid evidence and no established obesity efficacy.
| Attribute | Sobetirome | Tesofensine |
|---|---|---|
| Human evidence | Peer-reviewed reviews describe historical Phase I oral exposure with short-term lipid target engagement, including substantial LDL-C reductions, but a fully retrievable primary clinical report remains limited and development did not yield an approved therapy. | A randomized Phase II obesity trial showed dose-dependent weight loss, and smaller physiology studies suggest appetite/satiety effects are more prominent than a large 24-hour energy-expenditure increase. Tesomet combination data exist in hypothalamic obesity. |
| Research focus | Dyslipidaemia, metabolic and neurodegenerative research | Obesity/weight-management research |
| Regulatory status | No FDA/EMA-approved sobetirome medicine identified. | Not FDA-approved; FDA has cited tesofensine as ineligible for use in US 503A compounding in enforcement material. |
| Route / formulation | This is not a peptide and should not be grouped with peptide pharmacology. | This is not a peptide. Research results do not validate unregulated oral capsules. |
Why these are compared
These compounds appear in the experimental weight/metabolic drugs evidence landscape, but they are not interchangeable. Sobetirome is small-molecule thyroid hormone receptor-beta agonist studied in dyslipidaemia, metabolic and neurodegenerative research; Tesofensine is small-molecule monoamine reuptake inhibitor studied in obesity/weight-management research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Sobetirome: Historical Phase I human exposure; no established clinical efficacy programme / not approved.
Tesofensine: Randomized Phase II human weight-loss evidence; unapproved.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head evidence. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.